MARAL PHARMA

Active

Private limited companyfounded 20233 yrs activeRue de Taillis-pré 421, 6200 Châtelet, BelgiumKBO/BCE: BE 0800.104.894

Summary

The computed 12-month bankruptcy probability of MARAL PHARMA is 2.0% (moderate). The 2025 annual accounts show equity of €165k and a net result of €66k. Equity is growing by ~68.5% per year across the filed fiscal years. Its solvency ranks better than 36% of 18280 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2025

61 / 100

Healthy

The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability77▲+2

Solvency43▲+8

Growth78=

Track record94

Bankruptcy probability, 12 months

2.0% Moderate

0%0.5%1.5%4%10%≥ 25%

Credit up to €10k at 30 days acceptable

Liquidity tight (current ratio 1.17 against 0.79 in 2024; short-term debt: 27.4% and cash: 13.8% of total assets), and 82.1% of the assets are financed with debt.

How do we compute the score and the probability?

Credit check for your own amount and term

Signals

Five signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 47

Relative position

BE, all sectors

reference

Sector 47

higher

← fewer bankruptcies more bankruptcies →

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

17.9%

Return on assets

7.2%

Age of the figures

9 mo

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-07-2026, 8 days ahead of the deadline.

NBB · 3 filings

Deviation from the deadline

2025

8 d early

2024

21 d early

2023

13 d early

← before the deadline after the deadline →

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

25-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity

€165k▲ 67.2%

2024 · €99k

2023: €30k 2024: €99k

2023 → 2025

Total assets

€921k▼ 3.5%

2024 · €954k

2023: €860k 2024: €954k

2023 → 2025

Net result

€66k▼ 3.6%

2024 · €69k

2023: €20k 2024: €69k

2023 → 2025

Working capital

€43k

2024 · €-80k

2023: €-110k 2024: €-80k

2023 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line202320242025Trend

Equity€30k-€99k▲ 231%€165k▲ 67.2%

Operating result€44k-€115k▲ 161%€112k▼ 3.2%

Net result€20k-€69k▲ 247%€66k▼ 3.6%

Turnover and EBIT margin not published: the micro schema does not require them.

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 3% below 2024.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €921k

67.9%

32.1%

Fixed assets €625k ▼ 5.5%

Current assets €295k ▲ 1.0%

Equity and liabilities €921k

17.9%

82.1%

Equity €165k ▲ 67.2%

Debt €756k ▼ 11.7%

Debt's share of the balance-sheet total falls from 89.7% to 82.1%. Equity is higher and debt is lower.

Key figures and ratios

2025 value · change against 2024

EBITDA

€163k▲

2024 · €163k

Cash flow

€118k▲

2024 · €116k

Current ratio

1.17▲

2024 · 0.79

Quick ratio

0.78▲

2024 · 0.39

Debt to equity

4.58▼

2024 · 8.68

ROE

40.2%▼

2024 · 69.7%

ROA

7.2%▼

2024 · 7.2%

Interest coverage

5.86▲

2024 · 5.64

Debt ≤ 1 year

€252k▼

2024 · €372k

Debt > 1 year

€504k▲

2024 · €483k

Income taxes

€18k▼

2024 · €18k

Staff costs

€119k▲

2024 · €94k

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Filed annual accounts As filed with the NBB · 2025 against 2024 · 52 lines

Balance sheet Code20242025

Assets

Total assets20/58€954k€921k▼

Formation expenses20€0€0=

Fixed assets21/28€662k€625k▼

Intangible fixed assets21€248k€218k▼

Tangible fixed assets22/27€414k€407k▼

Land and buildings22€390k€387k▼

Plant, machinery and equipment23€21k€14k▼

Furniture and vehicles24€4k€6k▲

Leasing and similar rights25€0-

Current assets29/58€292k€295k▲

Stocks and contracts in progress3€146k€98k▼

Stocks30/36€146k€98k▼

Amounts receivable within one year40/41€65k€68k▲

Trade receivables40€65k€67k▲

Other amounts receivable41€4€1k▲

Cash at bank and in hand54/58€81k€127k▲

Deferred charges and accrued income490/1€236€2k▲

Equity and liabilities

Total equity and liabilities10/49€954k€921k▼

Equity10/15€99k€165k▲

Contributions10/11€10k€10k=

Profit (loss) carried forward14€89k€155k▲

Amounts payable17/49€856k€756k▼

Amounts payable after more than one year17€483k€504k▲

Financial debts170/4€483k€504k▲

Amounts payable within one year42/48€372k€252k▼

Current portion of amounts payable after more than one year42€60k€62k▲

Financial debts43€98k€0▼

Credit institutions430/8€98k€0▼

Trade debts44€118k€114k▼

Suppliers440/4€118k€114k▼

Taxes, remuneration and social security45€46k€49k▲

Taxes450/3€22k€24k▲

Remuneration and social security454/9€24k€25k▲

Other amounts payable47/48€51k€27k▼

Accrued charges and deferred income492/3-€0

Income statement Code20242025

Remuneration, social security and pensions62€94k€119k▲

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€47k€52k▲

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4-€0

Other operating charges640/8€2k€3k▲

Non-recurring operating charges66A€59-

Gross operating margin9900€259k€285k▲

Operating profit (loss)9901€115k€112k▼

Financial income75/76B€2€5▲

Recurring financial income75€2€5▲

Financial charges65/66B€29k€28k▼

Recurring financial charges65€29k€28k▼

Profit (loss) for the period before taxes9903€87k€84k▼

Income taxes67/77€18k€18k▼

Profit (loss) for the period9904€69k€66k▼

Profit (loss) for the period to be appropriated9905€69k€66k▼

Appropriation of the result

Profit (loss) to be appropriated9906€89k€155k▲

Profit (loss) brought forward from the previous period14P€20k€89k▲

The notes to these accounts (13 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Timeline · acts, filings and financial milestones

All 5Financial 2Filings 3

Next filing, fiscal year 2026, expected by 31-07-2027

2026

23-07

NBB filing Annual accounts filed

fiscal year 2025 · micro schema

2025

31-12

Financial Equity above €150kEq €165k ▲67.2%

3 profitable years in a row build equity to €165k.

10-07

NBB filing Annual accounts filed

fiscal year 2024 · micro schema

2024

31-12

Financial Highest result since 2023net €69k ▲247%

Operating result €115k, net result €69k, both a record.

18-07

NBB filing Annual accounts filed

fiscal year 2023 · micro schema

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

0 of 1 act read

About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Châtelet · 1 establishment unit since 2023

seat establishment The establishment unit on the map

Ground area

171 m²

Building footprint

158 m²

Parcel 52013A0013/00Z075, Wallonia. Linked by address, not a title deed.

1 establishment unit

MARAL PHARMA

Rue de Taillis-pré 421, 6200 ChâteletRetail sale of pharmaceutical products

since 20232.343.413.595

1 parcel

Wallonia 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
52013A0013/00Z075	Wallonia	171 m²	1 · 158 m²	-

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Recognitions · licences · registrations

Food safety, FASFC

1 site

Châtelet2.343.413.595

1 permission

Apotheek (LM>3 maand) · since 04-11-2025

Similar companies · same sector, comparable size

PHARMACIE DES TROIS ROIS

Frameries · Eq €165,161

Soumagne · Eq €165,272

Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,574 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded29-03-2023

Fiscal year end31-12

Activities, NACEBEL 2025

47730Retail sale of pharmaceutical products

Sources

Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.